Table 1.
Summary of neurological symptoms observed in study animals
| Animal ID | Vector dose | Symptom onset (days) | Survival (days) | Clinical signs |
|---|---|---|---|---|
| 0908068 | 1 × | 14 | 20 | Lethargy, unresponsive |
| 0908087 | 1 × | 17 | 23 | Ataxia, unable to perch |
| 0909589 | 1 × | 27 | 28 | Generalized weakness especially of right leg, reduced food intake |
| 8722431552 | 1/10th | 33 | 57 | Dyskinesias, chorea |
| 09087133 | 1/10th | 48 | ≥ Endpoint | Dyskinesias, chorea |
| 0909587 | 1/30th | 59 | 66 | Loss of voluntary use of right arm, eventual lethargy |
| 0908997 | 1/30th | n/a | ≥ Endpoint | None |
| 8963934563 | PBS | n/a | ≥ Endpoint | None |
| 5347096796 | TGE (1 × ) | n/a | ≥ Endpoint | None |
| 7667353701 | TGE (1 × ) | n/a | ≥ Endpoint | None |
For each animal, vector dose, day of symptom onset, length of survival, and observed clinical signs are indicated. The predetermined endpoint of the study was 90 days.
TGE, transgene empty; PBS, phosphate-buffered saline.